Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries.
R&D:Eveliqure has developed a novel vaccine technology platform based on a live attenuated vaccine strain of the bacterium Shigella, engineered to induce broad protection against infection caused by different species and serotypes. Eveliqure has also introduced the expression of non-shigella derived antigens into the strain to achieve protection against multiple pathogens. ShigETEC, is the first-generation vaccine candidate that targets Shigella and ETEC, two of the major pathogens causing diarrhea.
Karl-Farkas-Gasse 22, 3rd floor
1030 Wien
Vienna
Contact: Gábor Somogyi (CEO)
Email: office@eveliqure.com
Website